Related references
Note: Only part of the references are listed.Update on castrate-resistant prostate cancer: 2010
Kiran Lassi et al.
CURRENT OPINION IN ONCOLOGY (2010)
Tissue Culture Media Supplemented With 10% Fetal Calf Serum Contains a Castrate Level of Testosterone
J. P. Michiel Sedelaar et al.
PROSTATE (2009)
Mechanisms mediating androgen receptor reactivation after castration
Xin Yuan et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2009)
Awakening guardian angels: drugging the p53 pathway
Christopher J. Brown et al.
NATURE REVIEWS CANCER (2009)
MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer
Oskar W. Rokhlin et al.
CANCER BIOLOGY & THERAPY (2008)
Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence
Kensuke Kumamoto et al.
CANCER RESEARCH (2008)
Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation
Mingxuan Xia et al.
CELL CYCLE (2008)
Expression of androgen receptor is negatively regulated by p53
Fatouma Alimirah et al.
NEOPLASIA (2007)
Molecular regulation of androgen action in prostate cancer
Scott M. Dehm et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2006)
Androgen receptor action in hormone-dependent and recurrent prostate cancer
Irina U. Agoulnik et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2006)
Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival
C. Sun et al.
ONCOGENE (2006)
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy
C Tovar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP
OW Rokhlin et al.
ONCOGENE (2005)
Androgen deprivation therapy for prostate cancer
N Sharifi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
The p53 pathway: positive and negative feedback loops
SL Harris et al.
ONCOGENE (2005)
Cell proliferation and apoptosis in prostate tumors and adjacent non-malignant prostate tissue in patients at different time-points after castration treatment
N Ohlson et al.
PROSTATE (2005)
MDM2 is a central node in the p53 pathway: 12 years and counting
GL Bond et al.
CURRENT CANCER DRUG TARGETS (2005)
Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines
MV Cronauer et al.
ONCOGENE (2004)
Androgen receptor in prostate cancer
CA Heinlein et al.
ENDOCRINE REVIEWS (2004)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation
ZM Mu et al.
PROSTATE (2004)
Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program
RB Shah et al.
CANCER RESEARCH (2004)
LuCaP 35: A new model of prostate cancer progression to androgen independence
E Corey et al.
PROSTATE (2003)
Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase
HK Lin et al.
EMBO JOURNAL (2002)
p53 represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino- to carboxyl-terminal interaction
JL Shenk et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease
V Nwosu et al.
HUMAN MOLECULAR GENETICS (2001)
The development of androgen-independent prostate cancer
BJ Feldman et al.
NATURE REVIEWS CANCER (2001)
Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials
JI Johnson et al.
BRITISH JOURNAL OF CANCER (2001)
Share Paper
